Baleeiro, R.B.; Bouwens, C.J.; Liu, P .; Di Gioia, C.; Dunmall, L.S.C.; Nagano, A.; Gangeswaran, R.; Chelala, C.; Kocher, H.M.; Lemoine, N.R.; et al. MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy. Oncoimmunology 2022 ,11, 2080329. [CrossRef] 31. Abd-Aziz, N.; Poh, C.L. Development of Peptide-Based Vaccines for Cancer. J. Oncol. 2022 ,2022 , 9749363. [CrossRef] [PubMed] 32. Stephens, A.J.; Burgess-Brown, N.A.; Jiang, S. Beyond Just Peptide Antigens: The Complex World of Peptide-Based Cancer Vaccines. Front. Immunol. 2021 ,12, 696791. Available online: https://www.frontiersin.org/journals/immunology/articles/10.338 9/fimmu.2021.696791/full (accessed on 24 March 2024). [CrossRef] [PubMed] 33. Mizukoshi, E.; Nakagawa, H.; Tamai, T.; Kitahara, M.; Fushimi, K.; Nio, K.; Terashima, T.; Iida, N.; Arai, K.; Yamashita, T.; et al. Peptide vaccine-treated, long-term surviving cancer patients harbor self-renewing tumor-specific CD8+ T cells. Nat.